BLTE BELITE BIO INC

Belite Bio to Host Webcast on April 3, 2023 to Discuss 2022 Full Year Financial Results

Belite Bio to Host Webcast on April 3, 2023 to Discuss 2022 Full Year Financial Results

SAN DIEGO, March 31, 2023 (GLOBE NEWSWIRE) -- , Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company targeting eye diseases with significant unmet medical needs, will host a live webcast on Monday, April 3, 2023, at 4:30 p.m. Eastern time to discuss the Company’s financial results for the full year ended December 31, 2022, and provide a general business update. The financial results will be issued in a press release on Friday, March 31, 2023.

Webcast Information:

Date:Monday, April 3, 2023
Time:4:30 p.m. Eastern time (1:30 a.m. Pacific time)
Webcast Link:

Webcast Link Instructions

You can join the live webcast by visiting the link above or the “Presentations & Events” section of the Company’s Investor Relations website at . A replay will be available approximately two hours after the event for 90 days.

About Belite Bio

Belite Bio is a San Diego based clinical stage biopharmaceutical drug development company targeting eye diseases with significant unmet medical needs, such as advanced age-related macular degeneration (commonly known as Geographic Atrophy or advanced Dry AMD) and Stargardt disease, and metabolic diseases. For more information, follow us on , , , or visit us at .

Media and Investor Relations Contact:

Jennifer Wu /

Tim McCarthy



EN
31/03/2023

Underlying

BLTEBELITE BIO INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BELITE BIO INC

 PRESS RELEASE
Free
BLTE BELITE BIO INC

Belite Bio to Host Webcast on March 2, 2026, to Discuss Preliminary, U...

Belite Bio to Host Webcast on March 2, 2026, to Discuss Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- , Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Monday, March 2, 2026, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update for the fourth quarter and full year ended December 31, 2025. ...

February 23, 2026 1 EN
 PRESS RELEASE
Free
BLTE BELITE BIO INC

Belite Bio Announces Participation at the 41st Asia-Pacific Academy of...

Belite Bio Announces Participation at the 41st Asia-Pacific Academy of Ophthalmology Congress (APAO) SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- , Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Company will participate in the upcoming Asia-Pacific Academy of Ophthalmology (APAO) 2026 Congress, taking place February 5-7, 2026 in Hong Kong. The presentations will include previously disclosed topli...

January 29, 2026 1 EN
 PRESS RELEASE
Free
BLTE BELITE BIO INC

Belite Bio Completes Enrollment in the DRAGON II Clinical Trial of Tin...

Belite Bio Completes Enrollment in the DRAGON II Clinical Trial of Tinlarebant for Stargardt Disease (STGD1) Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in Stargardt disease, having met the primary endpoint in the pivotal, global Phase 3 DRAGON trial with 36% reduction in lesion growth (p-value=0.0033)60 adolescent STGD1 subjects enrolled in DRAGON II clinical trial across Japan, the United States, and the United KingdomBelite Bio plans to file a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) in 1H 2026 SAN DIEGO, Jan. 27, 2...

January 27, 2026 1 EN
 PRESS RELEASE
Free
BLTE BELITE BIO INC

Belite Bio Announces Pricing of $350.0 Million Underwritten Public Off...

Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it has priced an underwritten public offering of 2,272,727 American Depositary Shares (“ADSs”), each representing one of its ordinary shares, at a public offering price of $154.00 per ADS. The C...

December 2, 2025 1 EN
 PRESS RELEASE
Free
BLTE BELITE BIO INC

Belite Bio Announces Proposed Underwritten Public Offering of American...

Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it has commenced an underwritten public offering of American Depositary Shares (“ADSs”), each representing one of its ordinary shares. All of the securities in the offering are to be sold by Belite Bio. In addit...

December 1, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch